Total: $2,393.88M

Company
(Symbol)#
(M)

Type Of
Financing

Number Of
Shares,
Units
Or Warrants

Amount
Raised
(M)

Investors; Placement
Agents; Details
(Date)@


Active Biotech
AB
(Sweden;
SSE:ACTI)

Rights issue

5.62S

SKK169
(US$21.5)

About 98.5% of the shares offered were subscribed to based on subscription rights; the shares were purchased at SEK30 each(7/7)

Adherex Technologies
Inc.
(AMEX:ADH)

Private
placement of
stock and
warrants

30.39S
and
9.1W

$8.5

The shares were sold at $0.28 each and the three- year warrants are exercisable at $0.35 per share; GlaxoSmithKline plc invested $3M in the deal; Leerink Swann & Co. and Versant Partners Inc. were placement agents (7/20)

Adventrx
Pharmaceuticals
Inc.
(AMEX:ANX)

Private
placement of
stock and
warrants

10.81S and 10.81W

$20

Investment funds controlled by Carl Icahn led the financing, which also included Viking Global Investors LP; the warrants are exercisable at $2.26 per share; CIBC World Markets was lead placement agent and RBC Capital Markets was co- agent (7/22)

AspenBio Inc.
(OTC BB:APNB)

Private placement of stock and warrants

0.56S and 0.56W

$0.49

The deal was the second closing of a financing that totaled about $3.6M; the five-year warrants are exercisable at $1.35 per share; Westminster Securities Corp. was placement agent (7/12)

BioDelivery
Sciences
International
Inc.
(BDSI)

Funding agreement

N/A

$7

Clinical Development Capital LLC will provide up to $7M in funding for Phase III trials of BDSI's BEMA Fentanyl product in exchange for a milestone payment and royalties on product sales (7/18)

Cel-Sci Corp.
(AMEX:CVM)

Private placement of stock and warrants

1.25S and 0.375W

$0.5

A single investor purchased the stock at $0.40 per share; warrant terms were not disclosed (7/19)

Cephalon
Inc.
(CEPH)

Private placement of convertible notes

N/A

$120

Underwriters exercised their option on another $120M in notes, bringing gross proceeds from the sale to $920M; the 2% notes due 2015 are convertible at $46.70 per common share; the notes were sold from a shelf registration (7/1)

CV
Therapeutics
Inc.
(CVTX)

Public offering of convertible notes

N/A

$19.5

Underwriters exercised their option on another $19.5M in notes, bringing total proceeds from the public offering to $149.5M; the 3.25% notes due 2013 are convertible into stock at about $27 per share; underwriters were Lehman Brothers, Merrill Lynch & Co., Citigroup and Deutsche Bank Securities (7/1)

Cytogen
Corp.
(CYTO)

Private placement of stock and warrants

3.1S and 0.776W

$14

Shares in the registered direct offering were sold at $4.50 each; the warrants are exercisable at $6 per share; the deal was made from an existing shelf registration (7/19)

GeneMedix
plc
(UK; LSE:GMX)

Private placement of stock and warrants

4.31S and 2.16W

£0.281 (US$0.5)

The funding is the second $0.5M taken from a potential total of $10M over three years from funds advised by Southridge Management LLP; the three-year warrants are exercisable at 7.25 pence per share (7/14)

Genentech
Inc.
(NYSE:DNA)

Private placement of notes

N/A

$2B

Genentech priced $500M of 4.4% notes due 2010, $1B of 4.75% notes due 2015, and $500M of 5.25% notes due 2035 (7/13)

Isotechnika
Inc.
(Canada;
TSE:ISA)

Bought-deal financing

8.9S

C$20 (US$16.6)

A syndicate of underwriters led by GMP Securities Ltd. and including Canaccord Capital Corp., National Bank Financial Inc. and TD Securities Inc. purchased the shares at C$2.25 each; the totals include the exercise of their overallotment option (7/12)

Labopharm
Inc.
(Canada;
TSE:DDS)

Debt financing

N/A

$10

Hercules Technology Growth Capital Inc. provided an 11.95% loan repayable on July 1, 2008; Hercules also got five-year warrants to purchase 543,104 Labopharm shares at $2.71 each (7/11)

Neurochem
Inc.
(Canada;
NRMX)

Warrants exercise

2.8S

C$8.8 (US$7.1)

Picchio Pharma Inc. exercised a warrant from a July 2002 private placement to purchase 2.8M shares; Picchio Pharma now owns about 26.4% of Neurochem (7/25)

Novavax Inc.
(NVAX)

Private placement of stock

4S

$4

The shares were sold from a shelf registration at $1 each; Lane Capital Markets LLC was placement agent (7/5)

Pharmacopeia
Drug Discovery
Inc.
(PCOP)

Private placement of stock

2.47S

$8.47

The shares were sold at $3.43 each, a 15% discount to a five-day average; Jefferies & Co. Inc. was the placement agent (7/28)

ReGen
Biologics Inc.
(OTC BB: RGBI)

Private placement of stock and warrants

13.9S and 3.48W

$11.8

The shares were sold at $0.85 each; the five-year warrants are exercisable at $1 per share (7/15)

Sirna
Therapeutics
Inc.
(RNAI)

Private placement of stock and warrants

17.5S and
6.3W

$28

The shares were sold at $1.60 each and the warrants are exercisable at $1.92 per share until July 2010; investors included Sprout Group, Oxford Bioscience Partners and Venrock Associates; Thomas Weisel Partners was placement agent, and Leerink Swann and Brean Murray were co-advisers (7/7)

Solexa
Inc.
(SLXA)

Private placement of stock and warrants

6S and 3W

$24

The financing was the second closing of a $32.5M round; the first part closed in April; the shares were sold at $4 each and the warrants are exercisable at $5 each; investors included Abingworth Management Ltd., Amadeus Capital Partners Ltd., Oxford Bioscience Partners and SV Life Sciences; SG Cowen & Co. LLC was placement agent (7/12)

SR Pharma
plc
(UK; AIM:SRA)

Private placement of stock

36.1S

£8.3 (US$14.6)

Separately, Introgen Therapeutics Inc. invested $3M in SR Pharma as part of a collaboration; Mulier Capital Ltd. was financial adviser for the placement (7/28)

Stem Cells
Sciences plc
(UK; AIM:STEM)

Private placement of stock

6.2S

£6 (US$10.5)

Stem Cells gained a public listing on the Alternative Investment Market in the financing; Collins Stewart plc brokered the deal (7/14)

Synthetic
Blood
International
Inc.
(OTC BB:SYBD)

Private placement of convertible debt and warrants

N/A and 8.4W

$1.85

Terms of the convertible debentures were not disclosed; the three-year warrants are exercisable at $0.242 per share; the investment was led by Palisades Master Fund and arranged by HPC Capital Management LLC (7/13)

Transgene SA
(France; TRGNY)

Private placement of stock and warrants

4.66S and 2.33W

€34.9 (US$42.2)

Most of the shares were placed in Europe; the one- year warrants are exercisable at €8.05 per share (7/11)

Xenomics Inc.
(OTC BB:XNOM)

Private placement of convertible stock and warrants

N/A and 0.387W

$2.77

The Series A convertible stock is convertible into common stock at $2.15 per share; the five-year warrants are exercisable at $3.25 per share (7/15)


Notes:

This chart does not include real estate or manufacturing plant financings.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange.

No Comments